Novartis reports positive Phase III trial results for its gene therapy in spinal muscular atrophy Type 2, plans regulatory ...

In a move that follows an increasingly common trend in biopharma M&A, Novartis is shedding sites ... its $4.8 billion deal for the oncology drug developer. Amgen charted a similar move last ...

Aetna is taking legal action against Pfizer, Novartis, Teva Pharmaceuticals and others, saying the list of drugmakers ...

The policies in the package would put guardrails around how PBMs can operate. Measures expected to be included would prohibit PBMs from linking their payments to drug prices in Medicare ...

SAE Media Group's 15th Annual Pre-Filled Syringes and Injectable Drug Devices Conference 2023 ... New Technologies Device Project Leader, Novartis Amber Witteman, Founder, Managing Director ...

BizWest’s most-read stories of 2024 included new developments, layoffs, business closures, lawsuits and an airport terminal.

The preliminary injunction means West Virginia is blocked from enforcing S.B. 325 against Novartis and AbbVie while the cases ... which includes a fine of $50,000 per violation for each package of ...

The controversy over Sirtris drugs reached a tipping point in January ... Switzerland–based Novartis and Amgen, had raised flags about artifacts in the assays. According to Uwe Schoenbeck ...

Novartis AG said a new experimental medicine improved motor function in children with a form of spinal muscular atrophy, the ...

A U.S. appeals court on Friday revived a whistleblower lawsuit accusing Swiss drugmaker Novartis of paying illegal kickbacks ...

Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...